Tolremo therapeutics, a Basel, Switzerland-based biotechnology company focused on preventing non-genetic drug resistance in cancer, raised USD39M in Series A funding.
The round was led by BioMedPartners, with participation from new investor Pierre Fabre Invest, as well as existing investors.
Led by CEO Stefanie Flückiger-Mangual, PhD, Tolremo therapeutics aims to prevent non-genetic cancer drug resistance by dismantling the earliest defense to targeted therapies. The company discovered a pivotal mechanism that governs critical transcriptional resistance pathways. Its clinical compound TT125-802 is an orally available small molecule inhibitor designed to block these survival techniques to improve the response rates and durability of established treatments.
The company intends to use the funds to accelerate TT125-802 into a first-in-human study in patients with solid tumors.
In conjunction with the financing, Julie M. Cherrington, PhD, an experienced life science executive with a track record of bringing drugs into the clinic through to commercialization, has been appointed as Chair of the Board of Directors. In addition, Francesco Hofmann, PhD, Head of R&D for Medical Care at Pierre Fabre Laboratories, joined the Scientific Advisory Board. Dr. Hofmann has extensive experience in accelerating the delivery of new therapeutics, having facilitated the clinical development of more than twelve novel cancer drugs.
FinSMEs
20/09/2023